New program combines supplements, prescriptions and longitudinal monitoring as longevity companies push further into healthcare delivery.
Elysium Health is stretching its footprint. Moving past consumer retail, the New York-based firm has unveiled The Elysium Longevity Institute (TELI) – a physician-led ecosystem bundling personalized supplements, prescriptions, peptides and continuous clinical support.
Best known for its NAD+-focused pills, Elysium claims this initiative will finally offer an individualized longevity roadmap. Backed by physician oversight and longitudinal monitoring, initial enrollment is strictly capped at 10,000 participants ahead of a 3Q 2026 launch. Longevity clinics are hardly a novelty in 2026, but Elysium’s structural evolution mirrors a broader tectonic shift. The wellness landscape is maturing; companies that once built franchises on isolated supplements, point-in-time diagnostics or clever digital tools are racing to construct integrated care models – bringing disparate interventions together under a single healthspan-focused umbrella.
Longevity.Technology: The real story here is not the clinical menu. The most interesting aspect of Elysium’s announcement may not be the supplements, prescriptions or even the trendy addition of peptides – it is the continued, almost aggressive blurring of the line between longevity consumerism and structured longevity medicine. Increasingly, companies are wagering that modern consumers are exhausted by a disjointed mosaic of disconnected tests, apps and standalone interventions – and they want an expert to join the dots. Whether this breed of integrated longevity care ultimately delivers better health outcomes than today’s fragmented wellness marketplace remains an open, tantalizing question, but it is rapidly becoming one of the sector’s most critical operational experiments.
The clinical pivot changes the data game entirely. For all the theoretical excitement surrounding longevity medicine, the field still suffers from an acute shortage of the one asset it needs most: robust human data collected over meaningful periods of time. Biomarkers are excellent signposts, sure, but they are not destinations. The real hurdle is demonstrating genuine, verifiable improvements in function, resilience and long-term disease risk rather than simply generating ever more numbers for anxious patients to monitor. Peptides arrive at a particularly prickly moment, too, with regulators training a sharper lens on a category that has often raced far ahead of its clinical evidence.
Meanwhile, the appointment of former UnitedHealth executive Omar Baker hints at something far more profound: the arrival of serious healthcare operators in a territory historically dominated by idealistic scientists, bold entrepreneurs and enthusiastic early adopters. Longevity has never lacked ambition; what it has occasionally lacked is actual infrastructure. The next phase of the industry’s evolution may entirely depend on whether it can build delivery systems that are every bit as rigorous as the exquisite biology it hopes to harness.
From products to programs
Founded in 2014, Elysium built its commercial reputation around translating complex aging research into consumer products, primarily through its extensive work on NAD+ metabolism. TELI represents a profound broadening of that original corporate thesis, pushing the company squarely into the direct delivery of healthcare services. Members will secure access to physician-guided interventions spanning healthy aging, metabolic health, recovery and performance, and detox and inflammation – including vitamin injections and targeted peptide-based approaches.
Leading the new venture will be Omar Baker, MD, former EVP and deputy chief medical officer at UnitedHealth Group, who recently joined the company as chief medical officer. Baker positioned the initiative as a deliberate attempt to inject greater clinical discipline into a rapidly expanding, often chaotic market.
“Elysium has helped define a new category at the intersection of consumer health and biopharma by grounding its approach in science,” he said. “While much of the longevity market is driven by narrative, Elysium has consistently invested in translational research – linking advances in aging biology, including NAD+ metabolism, to measurable health outcomes.”
He added that TELI aims to bring “clinical-grade rigor, physician oversight, and longitudinal data tracking to telehealth” and, in doing so, move the conversation “from promise to proof.”
Building on a longevity science foundation
The company maintains the program culminates a decade of development and academic collaboration. Elysium co-founder Leonard Guarente, PhD – the Novartis Professor of Biology at MIT and a pioneer of sirtuin research – framed the initiative as a direct continuation of their long-standing obsession with scientific validation.
“When we founded Elysium, both the longevity industry and dietary supplements lacked credibility,” said Guarente. “We fundamentally changed consumer health by engaging many of the world’s best scientists and aging research institutions to develop products grounded in scientific and clinical rigor.”
Guarente added that the company intends to apply the exact same model to “longevity-focused medicine, including testing, prescription products, and next-generation solutions such as peptides.”
That final point will undoubtedly attract intense scrutiny. Peptides have swiftly become one of the fastest-growing segments of longevity medicine, yet evidence quality remains frustratingly uneven across different compounds and indications. Their meteoric popularity has also drawn inevitable regulatory friction; in July, the US Food and Drug Administration’s Pharmacy Compounding Advisory Committee is scheduled to review several peptides for potential inclusion on the Section 503A Bulk Drug Substances List.
An evolving market
For Elysium chief executive Eric Marcotulli, the launch reflects a longer-term evolution that began with the company’s initial focus on NAD+ biology.
“Both consumer interest in NAD+ and the science behind it were nascent when we started Elysium,” he said. “Today, it is everywhere – NAD+ has unquestionably gone mainstream.”
Marcotulli described TELI as “our most ambitious expansion” and argued that the company is uniquely positioned to bridge consumer health and the pharmaceutical sector while maintaining strict quality and safety standards.
Whether that specific vision proves successful remains to be seen. As longevity medicine matures, the competitive landscape will favor scale – and survival will likely belong to organizations capable of combining scientific credibility, clinical oversight and large-scale data collection within a single, tidy framework.
The next test
The tools exist. Longevity medicine has spent years assembling an impressive toolkit – biomarkers, diagnostics, therapeutics, digital monitoring and a growing understanding of the biology of aging. The trickier task ahead will be determining how those pieces fit together in the real world. Programs such as TELI will be watched closely not just for the immediate services they provide, but for what they can reveal about the practical delivery of preventive, longevity-focused healthcare at scale.
